Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

Boeing (BA) Wins $280M Deal To Support SDBI Weapon System

Published 09/26/2019, 10:47 PM
Updated 07/09/2023, 06:31 AM
BA
-
LMT
-
RTN
-
HEI
-

The Boeing Company’s (NYSE:BA) Defense, Space, and Security unit (BDS) recently secured a $280-million deal to provide engineering support to the Small Diameter Bomb (SDB) I weapon system. The contract was awarded by
the Air Force Life Cycle Management Center, Eglin Air Force Base, FL.

Per the terms, the BDS unit will provide SDB weapon integration on selected weapon platforms and support the fielded weapon system. Work related to the deal will be performed in St. Louis, MO, and is scheduled to be completed by September 2024.

SDB’S Growing Importance Among Global Militaries

With increased cross-border tensions across the globe, both developed and developing countries have been ramping up their defense arsenal over the past decade. Notably, bombs and other major munitions comprise a significant part of the weapon portfolio.

To this end, munitions like SDB’s have seen its importance grow over the years, as militaries of Australia, Belgium, Canada, Denmark, Greece, Israel, South Korea, the Netherlands, Spain, Sweden, Turkey and Singapore have opted for these bombs as one of their preferred choice of munition. Such global acceptance of these bombs significantly benefits its makers like Boeing and Raytheon (NYSE:RTN) .

Global Prospects of the Munitions Market

Per Grand View Research, the global munitions market is expected to see a CAGR of 3.5% by 2024 to reach $16 billion. Such growth can be attributed to the rise in terrorism accompanied by continuous stacking of arms and weapons in emerging economies, owing to rising defense expenditures. Such projections, on a whole, should enable Boeing to significantly grow in the expanding global munitions market in the days ahead.

Our View

Boeing’s SDB is one of the very few weapon systems of its kind in the global munitions market. Being one of the largest defense contractors in the United States, Boeing serves the U.S. aerospace and defense industry and its allies by producing, integrating and supporting precise, long-range and focused munition capabilities. Currently, the demand for SDB is high, given the fact that apart from the United States, eight foreign allies of the country use this precision weapon.

With more nations bumping up their defense spending, Boeing consistently enjoys frequent order flow from international markets for advanced weapons like SDB. The latest contract win is a further testament to that.

Furthermore, the fiscal 2020 defense budget reflects a solid spending provision of $5.1 billion for munitions. Such allocations should usher in more contracts for renowned munition manufacturers like Boeing.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Price Performance

In the past month, Boein's stock has gained 7.5% compared with the industry’s 5% growth.



Zacks Rank & Key Picks

Boeing currently carries a Zacks Rank #3 (Hold).

A few better-ranked stocks in the same sector are Lockheed Martin Corporation (NYSE:LMT) and Heico Corporation (NYSE:HEI) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Lockheed Martin came up with average positive earnings surprise of 16.03% in the last four quarters. The Zacks Consensus Estimate for 2019 earnings has increased 3.31% to $21.20 in the past 60 days.

Heico came up with average positive earnings surprise of 1.19% in the last four quarters. The Zacks Consensus Estimate for 2019 earnings has risen 4.1% to $2.30 over the past 60 days.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>



Lockheed Martin Corporation (LMT): Free Stock Analysis Report

The Boeing Company (BA): Free Stock Analysis Report

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .
Heico Corporation (HEI): Free Stock Analysis Report

Raytheon Company (RTN): Free Stock Analysis Report

Original post

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.